227 related articles for article (PubMed ID: 17058739)
21. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
Vlastos G; Mirza NQ; Lenert JT; Hunt KK; Ames FC; Feig BW; Ross MI; Buzdar AU; Singletary SE
Cancer; 2000 Mar; 88(6):1417-24. PubMed ID: 10717625
[TBL] [Abstract][Full Text] [Related]
22. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results.
Beriwal S; Schwartz GF; Komarnicky L; Garcia-Young JA
Breast J; 2006; 12(2):159-64. PubMed ID: 16509842
[TBL] [Abstract][Full Text] [Related]
23. Serial integrated (18)F-fluorodeoxythymidine PET/CT monitoring neoadjuvant chemotherapeutic response in invasive ductal carcinoma.
Beresford M; Lyburn I; Sanghera B; Makris A; Wong WL
Breast J; 2007; 13(4):424-5. PubMed ID: 17593051
[No Abstract] [Full Text] [Related]
24. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
25. Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients.
Shin HC; Han W; Moon HG; Im SA; Moon WK; Park IA; Park SJ; Noh DY
Ann Surg Oncol; 2013 Aug; 20(8):2582-9. PubMed ID: 23504119
[TBL] [Abstract][Full Text] [Related]
26. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy.
Thomas F; Arriagada R; Spielmann M; Mouriesse H; Le Chevalier T; Fontaine F; Tursz T
Cancer; 1995 Dec; 76(11):2286-90. PubMed ID: 8635033
[TBL] [Abstract][Full Text] [Related]
27. Complete axillary conversion after neoadjuvant chemotherapy in locally advanced breast cancer: a step towards conserving axilla?
Arimappamagan A; Kadambari D; Srinivasan K; Krishnan R; Elangovan S; Reddy KS
Indian J Cancer; 2004; 41(1):13-7. PubMed ID: 15105574
[TBL] [Abstract][Full Text] [Related]
28. Early response to neo-adjuvant chemotherapy in carcinoma of the breast predicts both successful breast-conserving surgery and decreased risk of ipsilateral breast tumor recurrence.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
Breast J; 2010; 16(1):9-13. PubMed ID: 19929889
[TBL] [Abstract][Full Text] [Related]
29. Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.
Moyses B; Haegele P; Rodier JF; Lehmann S; Petit T; Velten M; Schraub S
Clin Breast Cancer; 2002 Jan; 2(4):304-10. PubMed ID: 11899363
[TBL] [Abstract][Full Text] [Related]
30. Preoperative chemotherapy for T2 breast cancer is associated with improved surgical outcome.
Karanlik H; Ozgur I; Cabioglu N; Sen F; Erturk K; Kilic B; Onder S; Deniz M; Yavuz E; Aydiner A
Eur J Surg Oncol; 2015 Sep; 41(9):1226-33. PubMed ID: 26141784
[TBL] [Abstract][Full Text] [Related]
31. [A case of HER2 overexpressing advanced breast cancer with CTF therapy [cyclophosphamide, pirarubicin (THPADM), fluorouracil] showed long-term effectiveness after paclitaxel shock].
Ikeda M; Sonoo H; Oota Y; Fujii S; Shimo T; Miyake A; Seki M; Nomura T; Yamamoto Y; Shiiki S; Nakashima K; Tanaka K; Kurebayashi J
Gan To Kagaku Ryoho; 2010 Dec; 37(13):2917-20. PubMed ID: 21160270
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
Wang LZ; Ouyang T; Wang TF; Xie YT; Fan ZQ; Fan T; Lin BY; Li JF
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):143-6. PubMed ID: 22780935
[TBL] [Abstract][Full Text] [Related]
33. [Two cases of breast cancer markedly responded to neoadjuvant chemoendocrine therapy (2 cycles of CMF and tamoxifen, pCR and near pCR)].
Rai Y; Sagara Y; Sagara Y; Ooi Y
Gan To Kagaku Ryoho; 2004 Mar; 31(3):443-7. PubMed ID: 15045959
[TBL] [Abstract][Full Text] [Related]
34. Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.
Chintamani ; Singhal V; Singh JP; Lyall A; Saxena S; Bansal A
BMC Cancer; 2004 Aug; 4():48. PubMed ID: 15310398
[TBL] [Abstract][Full Text] [Related]
35. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.
Sataloff DM; Mason BA; Prestipino AJ; Seinige UL; Lieber CP; Baloch Z
J Am Coll Surg; 1995 Mar; 180(3):297-306. PubMed ID: 7874340
[TBL] [Abstract][Full Text] [Related]
36. Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option.
Haberer S; Belin L; Le Scodan R; Kirova YM; Savignoni A; Stevens D; Moisson P; Decaudin D; Pierga JY; Reyal F; Campana F; Fourquet A; Bollet MA
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e145-52. PubMed ID: 21605948
[TBL] [Abstract][Full Text] [Related]
37. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
38. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer.
Peintinger F; Kuerer HM; McGuire SE; Bassett R; Pusztai L; Symmans WF
Br J Surg; 2008 Apr; 95(4):433-7. PubMed ID: 18161887
[TBL] [Abstract][Full Text] [Related]
39. Influence of smoking history on breast cancer prognosis: retrospective study of 240 operable breast cancer patients who received adjuvant cyclophosphamide, doxorubicin, and 5-fluorouracil chemotherapy regimen.
Aksoy S; Harputluoglu H; Guler N; Altundag K; Hayran M; Tekuzman G; Ozisik Y
Breast J; 2007; 13(4):431-2. PubMed ID: 17593056
[No Abstract] [Full Text] [Related]
40. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
